Anavex will evaluate the safety, maximally tolerated dose, pharmacokinetics and pharmacodynamics in the Phase I trial.
Anavex-2-73 represents a new class of wholly owned compounds that act through sigma-1 receptor agonism, and muscarinic, cholinergic effects and modulation of endoplasmic reticulum stress leading to a series of intracellular effects to modify ion channel signalling at the mitochondrial level.
ANAVEX 2-73 is the first of a new class of oral, disease-modifying drugs being studied to treat Alzheimer’s disease rather than treating its symptoms.
The Phase I trial of ANAVEX 2-73 will be conducted in collaboration with ABX-CRO and the University of Dresden in Germany.